About
Dayton Misfeldt is a Partner at Decheng Capital, which he joined in January 2021. He was previously a Managing Director at Bay City Capital, where he invested in biopharmaceutical companies and supported management teams on strategy, business development, and exits, and earlier worked as a sell-side analyst at Roth Capital Partners and in consulting at LifeScience Economics. He holds a BA in Economics from the University of California, San Diego.
Invests in
Biotech
Experience
- Decheng CapitalPartnercurrent2021 — presentMenlo Park, California, United States
- Bay City CapitalPartner2000 — 2020
Education
- UC San Diego
Skills & more
Venture Capital7Lifesciences5Pharmaceutical Industry6
From Dayton's professional profile.
Same school
Also attended UC San Diego187
Mark SusterManaging Partner at Upfront VenturesBirgitteInvestor at InvestinorHouman HaghighiPartner, Business & Corporate Development at Menlo VenturesFreya Svedberg-KeatingInvestor at MedicxiJamie MontgomeryCo-Founder & Managing Partner at March Capital PartnersAbbie CelnikerInvestor at Third Rock Ventures
+ 181 more
Investments
Board seats
ExcellergyUpstream Bio
Investor
Cadence PharmaceuticalsCivitas TherapeuticsDermiraExcellergyMAP PharmaceuticalsNextwave PharmaceuticalsOculex PharmaceuticalsPharmion
Per the firm's website.
Colleagues at Decheng Capital
Aaron Li
Principal at Decheng Capital
Claire Zhang
Senior Associate at Decheng Capital
Joan Chen
Vice President at Decheng Capital
Katherine Xu
Partner at Decheng Capital
Michael Notaras
Vice President at Decheng Capital
Min Cui
Founder and Managing Director at Decheng Capital
Nick Pliam
Venture Partner at Decheng Capital
Peter Colabuono
Managing Director at Decheng Capital